COVID-19 and myotonic dystrophy: Case reports and systematic review
The Journal of Infection in Developing Countries · 2023
DOI: 10.3855/jidc.15653 ↗At a glance
Fallbericht in The Journal of Infection in Developing Countries, 2023. Written by Maria Mazzitelli and 4 co-authors. Institution: Infectious and Tropical Diseases Unit, Padua Hospital, Padua, Italy. Major MEDLINE topics: Myotonic Dystrophy, COVID-19. Cited 3 times so far (Crossref). The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Introduction
Steinert's disease is a rare genetic disorder characterized by progressive myotonia and multi-organ damage. It is associated with respiratory and cardiological complications often leading patients to exitus. These conditions are also traditional risk factors for severe COVID-19. SARS-CoV-2 has affected people with chronic diseases, but the impact on people with Steinert's disease is poorly defined, with only a few reported and described. More data are needed to understand whether this genetic disease is a risk factor for more serious evolution or death in patients with COVID-19. Methodology: The study describes two cases of patients with SD and COVID-19 and summarizes available evidence of the clinical outcome of COVID-19 in patients with Steinert's disease, by performing a systematic review of the literature (following PRISMA statements and performing PROSPERO registration).
Results
Overall, 5 cases were retrieved from the literature review, with a median age of 47 years, of whom 4 had advanced SD and unfortunately died. By contrast, the 2 patients from our clinical practice and 1 from literature had a good clinical outcomes. Mortality ranged from 57% (all cases) to 80% (only literature review).
Conclusions
There is a high mortality rate in patients with both Steinert's disease and COVID-19. It highlights the importance of strengthening prevention strategies, especially vaccination. All SD with SARS-CoV-2 infection/COVID-19 patients should be identified early and treated to avoid complications. It is still unknown which treatment regimen is best to use in those patients. Studies on a greater number of patients are necessary to provide clinicians with further evidence.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Infectious and Tropical Diseases Unit, Padua Hospital, Padua, Italy.
- Respiratory Disease Unit, Department of Cardiac Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Cite
APA
Mazzitelli, M., Trevenzoli, M., Brundu, M., Squarzoni, G., & Cattelan, A. M. (2023). COVID-19 and myotonic dystrophy: Case reports and systematic review. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.15653
Vancouver
Mazzitelli M, Trevenzoli M, Brundu M, Squarzoni G, Cattelan AM. COVID-19 and myotonic dystrophy: Case reports and systematic review. The Journal of Infection in Developing Countries. 2023. doi:10.3855/jidc.15653
BibTeX
@article{Mazzitelli2023,
author = {Mazzitelli, Maria and Trevenzoli, Marco and Brundu, Monica and Squarzoni, Giulia and Cattelan, Anna Maria},
title = {COVID-19 and myotonic dystrophy: Case reports and systematic review},
journal = {The Journal of Infection in Developing Countries},
year = {2023},
doi = {10.3855/jidc.15653}
}
EUVIMED